Discovery is a complex and high-risk process in drug development, as researchers strive to identify and advance promising therapeutic candidates. It requires scientific prowess, advanced technologies, and strategic vision to navigate through potential obstacles with agility. With this episode, Big4Bio is kicking off an occasional series on discovery sciences with Charles River Labs, which, over the past five years, has contributed to more than 80 percent of novel FDA-approved drugs. We spoke with Charles River Labs' chief scientific officer of discovery Justin Bryans, and Charles River Labs' vice president and chief scientific officer for discovery and safety assessments, Steve Bulera, about the challenges of drug discovery, why every moment matters, and the benefits of the collaborative approach Charles River takes in working with its partners.
All content for The Big4Bio Podcast is the property of Big4Bio and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Discovery is a complex and high-risk process in drug development, as researchers strive to identify and advance promising therapeutic candidates. It requires scientific prowess, advanced technologies, and strategic vision to navigate through potential obstacles with agility. With this episode, Big4Bio is kicking off an occasional series on discovery sciences with Charles River Labs, which, over the past five years, has contributed to more than 80 percent of novel FDA-approved drugs. We spoke with Charles River Labs' chief scientific officer of discovery Justin Bryans, and Charles River Labs' vice president and chief scientific officer for discovery and safety assessments, Steve Bulera, about the challenges of drug discovery, why every moment matters, and the benefits of the collaborative approach Charles River takes in working with its partners.
One of the reasons that drug development is so expensive and time consuming is the cost of clinical trial failures. A critical means of accelerating drug development and reducing its cost lies in identifying candidates during preclinical development that have risks that outweigh their benefits and eliminating them from the pipeline before they advance to the clinic. We spoke to Sarah Gould, Director and Senior Principal Scientific Advisor for Charles River Labs, about the types of risks that can be detected through preclinical testing, strategies that can be used to de-risk programs, and why doing so in the current environment can take on growing importance for companies seeking funding or licensing agreements.
The Big4Bio Podcast
Discovery is a complex and high-risk process in drug development, as researchers strive to identify and advance promising therapeutic candidates. It requires scientific prowess, advanced technologies, and strategic vision to navigate through potential obstacles with agility. With this episode, Big4Bio is kicking off an occasional series on discovery sciences with Charles River Labs, which, over the past five years, has contributed to more than 80 percent of novel FDA-approved drugs. We spoke with Charles River Labs' chief scientific officer of discovery Justin Bryans, and Charles River Labs' vice president and chief scientific officer for discovery and safety assessments, Steve Bulera, about the challenges of drug discovery, why every moment matters, and the benefits of the collaborative approach Charles River takes in working with its partners.
